MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MYX - MAYNE PHARMA GROUP LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 22.1
Index: ASX300 | ALL-ORDS
Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$3.78
08 Jun |
OPEN $3.85 |
HIGH $3.88 |
541,433 LOW $3.70 |
-0.100| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BNO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -320.0 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 424.8 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 640.0 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -16.6 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -61.99 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -39.51 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -32.28 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -18.94 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -39.51 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -5.97 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -26.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 408 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 6 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 414 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 65 M |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 97 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.78 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 11.9 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 2.79 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 319 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 168 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 14 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MYX STOCK CHART
FNArena News on MYX
| 1 |
Australian Broker Call *Extra* Edition – May 16, 2023May 16 2023 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Mar 15, 2023Mar 15 2023 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Mar 10, 2023Mar 10 2023 - Daily Market Reports |
| 4 |
The Short Report – 16 Feb 2023Feb 16 2023 - Weekly Reports |
| 5 |
Australian Broker Call *Extra* Edition – Dec 07, 2022Dec 07 2022 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: DimerixJun 07 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Chimeric TherapeuticsMay 26 2023 - Small Caps |
| 3 |
Avita Medical Preps For Enlarged US OpportunityMay 17 2023 - Small Caps |
| 4 |
Dr Boreham’s Crucible: Radiopharm TheronosticsApr 13 2023 - Small Caps |
| 5 |
Dr Boreham’s Crucible: Avita MedicalMar 29 2023 - Small Caps |
| 6 |
Telix Pharmaceuticals’ Pipeline Full Of PromiseMar 21 2023 - Small Caps |
| 7 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
| 10 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
